Pitobrutinib effects and side effects

Pittobrutinib, the active ingredient inJaypirca, exerts its therapeutic effect by precisely blocking an enzyme called BTK. The BTK enzyme plays a crucial role in the growth process of B cells, especially for the abnormally proliferating B cells in patients with mantle cell lymphoma, and is the key to their survival and spread. Pitobrutinib can effectively inhibit the activity of BTK enzyme, which is expected to slow down the progression of the disease and provide a new treatment strategy for patients who are deeply troubled by lymphoma.

However, like many other drugs, pitobrutinib may be associated with some side effects. Based on data from clinical trials and real-world applications, we know that the most common side effects among patients taking Jaypirca include fatigue, neutropenia, diarrhea, and bruising. Although these side effects may cause some discomfort to patients, they are usually within a controllable and acceptable range.

In addition, there are some more serious side effects that require our attention. Side effects such as pneumonia, anemia and urinary tract infections may affect up to 1 in 10 patients. The occurrence of pneumonia may be related to drug suppression of the immune system, while anemia may be due to drug interference with red blood cell production. Urinary tract infections may be caused by irritation of the urinary tract system during excretion of drugs. Although the occurrence probability of these side effects is relatively low, if they occur, timely medical intervention and treatment are required.

In general, as a new type of lymphoma treatment drug, pitobrutinib shows its significant efficacy but is also accompanied by a certain risk of side effects. Therefore, during use, patients need to pay close attention to changes in their physical condition and communicate with their doctors in a timely manner to ensure the safety and effectiveness of the drug.

xa0

Reference: https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca